MedPath
HSA Approval

TAZIME FOR INJECTION 1 g/vial

SIN12096P

TAZIME FOR INJECTION 1 g/vial

TAZIME FOR INJECTION 1 g/vial

October 11, 2002

SHOEI UNIVERSAL CORPORATION PTE LTD

SHOEI UNIVERSAL CORPORATION PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSHOEI UNIVERSAL CORPORATION PTE LTD
Licence HolderSHOEI UNIVERSAL CORPORATION PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, FOR SOLUTION

INTRAVENOUS, INTRAMUSCULAR

Medical Information

J01DD02

ceftazidime

Manufacturer Information

SHOEI UNIVERSAL CORPORATION PTE LTD

HANMI PHARM CO LTD

Active Ingredients

Ceftazidime pentahydrate with sod. carbonate1.121g/vial eqv Ceftazidime Pentahydrate

1 g/vial

Ceftazidime

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TAZIME FOR INJECTION 1 g/vial - HSA Approval | MedPath